MicroRNA-141-5p Acts as a Tumor Suppressor via Targeting RAB32 in Chronic Myeloid Leukemia

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• MicroRNA-141-5p (miR-141-5p), part of the miR-200 family, influences cancer cell behaviors like proliferation, migration, invasion, and drug resistance.
• The specific role of miR-141-5p in chronic myeloid leukemia (CML) remains largely uncharacterized.

Purpose of the Study:

• To investigate the function and role of miR-141-5p in chronic myeloid leukemia (CML).
• To explore the potential therapeutic implications of miR-141-5p in CML treatment.

Main Methods:

• Quantitative analysis of miR-141-5p levels in CML patients and cell lines.
• In vitro studies assessing the effects of miR-141-5p suppression and overexpression on K562 cell proliferation, migration, and apoptosis.
• In vivo studies using a xenograft mouse model to evaluate tumor growth.
• Mechanistic studies to identify potential targets of miR-141-5p.

Main Results:

• miR-141-5p levels were significantly decreased in CML patient blood cells and K562 cells compared to normal controls.
• miR-141-5p levels increased in CML patients treated with nilotinib or imatinib.
• Suppression of miR-141-5p enhanced K562 cell proliferation and migration, while its overexpression reduced proliferation, migration, and increased apoptosis.
• Overexpression of miR-141-5p suppressed tumor growth in a xenograft model.
• RAB32 was identified as a potential target of miR-141-5p; silencing RAB32 mimicked the effects of miR-141-5p overexpression.

Conclusions:

• miR-141-5p functions as a tumor suppressor in chronic myeloid leukemia (CML).
• miR-141-5p targets RAB32, influencing K562 cell proliferation, migration, and apoptosis.
• The findings suggest miR-141-5p may serve as a potential therapeutic biomarker or target in CML treatment.